Registered title, quoted from ClinicalTrials.gov
Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Guangzhou Medical University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06286150, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 3
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (3 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Patients positive for Human Immunodeficiency Virus (HIV) antibodies or syphilis seropositive patients.
Exclusion criterion 5
Women who are pregnant, breastfeeding, or planning to become pregnant during the trial period.
Exclusion criterion 8
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06286150, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age between 18 and 75 years, regardless of gender.
- Patients who require endoscopic surgical treatment and have indications for lung segment/lobe resection; for pre-trial subjects, there is no restriction on the type of procedure, and inclusion is based on the investigator's judgment of having indications for thoracic surgery.
- Preoperative ASA classification of I-III.
- Voluntary participation in the clinical trial and willingness to provide informed.
consent, either by the subject or their guardian.
- Willingness to cooperate and complete trial follow-up and related examinations.
Exclusion Criteria:
- Patients with a history of thoracic surgery or previous history of other malignant tumors deemed unsuitable for inclusion by the investigator.
- Patients with severe comorbidities (cardiac, pulmonary, hepatic, cerebral, renal diseases) or physical weakness who cannot tolerate general anesthesia or surgery.
- Patients with severe bleeding tendencies or coagulation disorders.
- Patients in the active phase of infectious diseases or with other severe non-communicable infections.
- Patients positive for Human Immunodeficiency Virus (HIV) antibodies or syphilis seropositive patients.
- Patients with a suspected or confirmed alcohol, drug, or substance addiction.
- Patients with a history of epilepsy, mental illness, or cognitive impairment.
- Women who are pregnant, breastfeeding, or planning to become pregnant during the trial period.
- Participation in other interventional clinical trials within 3 months prior to signing the informed consent form.
- Other situations in which the investigator deems inappropriate for participation in this clinical trial.
Quoted from ClinicalTrials.gov, NCT06286150, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06286150, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.